-
11.
公开(公告)号:ZA200704151B
公开(公告)日:2008-08-27
申请号:ZA200704151
申请日:2007-05-22
Applicant: SOLVAY PHARM BV
Inventor: ROELOF VAN HES , KRUSE CORNELIS G , PIETER SMID , TULP MARTINUS TH M
IPC: A61K20090101 , A61P20090101 , C07D20090101
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula ( 1 ) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:AR061357A1
公开(公告)日:2008-08-20
申请号:ARP070102582
申请日:2007-06-13
Applicant: SOLVAY PHARM BV
Inventor: TULP MARTINUS TH M , MCCREARY ANDREW C , VAN SCHARRENBURG GUSTAAF J M
IPC: A61K31/135 , A61K31/496 , A61P25/14 , A61P25/16
Abstract: La presente se refiere al uso de una preparacion combinada de bifeprunox o su N-oxido o sales farmacéuticamente aceptables de estos compuestos: y L-DOPA, para el uso simultáneo, separado o secuencial en el tratamiento de trastornos que requieren la recuperacion de la funcion dopaminérgica, en particular la enfermedad de Parkinson y el síndrome de las piernas inquietas. Composicion farmacéutica, método de tratamiento.
-
公开(公告)号:AR061355A1
公开(公告)日:2008-08-20
申请号:ARP070102580
申请日:2007-06-13
Applicant: SOLVAY PHARM BV
Inventor: VAN SCHARRENBURG GUSTAAF J M , TULP MARTINUS TH M , MCCREARY ANDREW C
IPC: A61K31/496 , A61K31/137 , A61P25/14 , A61P25/16
Abstract: La invencion se refiere al uso de una preparacion de combinacion de SLV308 o su N-oxido o sales farmacéuticamente aceptables de estos compuestos, y L-DOPA, para el uso simultáneo, separado o secuencial en el tratamiento de trastornos qué requieren la recuperacion de la funcion dopaminérgica, en particular la enfermedad de Parkinson y el síndrome de las piernas inquietas. Reivindicacion 2: Una preparacion de acuerdo con la reivindicacion 1, caracterizada porque comprende además un inhibidor de descarboxilasa. Reivindicacion 4: Una preparacion de acuerdo con cualquiera de las reivindicaciones 1, 2 o 3, caracterizada porque comprende además un inhibidor de MAO-B. Reivindicacion 8: Una composicion farmacéutica, caracterizada porque comprende, además de un excipiente farmacéuticamente aceptable y/o al menos una sustancia auxiliar farmacéuticamente aceptable, como ingrediente activo una cantidad farmacologicamente activa de una preparacion de cualquiera de las reivindicaciones 1- 4. Reivindicacion 9: Un método para tratar la enfermedad de Parkinson o el síndrome de las piernas inquietas en un paciente humano o animal que necesita tal tratamiento, método caracterizado porque comprende administrar al paciente simultáneamente, separadamente o secuencialmente una cantidad de SLV308 o su N-oxido o una sal farmacologicamente aceptable de los mismos, y una cantidad de L-DOPA, donde las cantidades son eficaces para el tratamiento.
-
公开(公告)号:NO20073389A
公开(公告)日:2007-07-05
申请号:NO20073389
申请日:2007-07-02
Applicant: SOLVAY PHARM BV
Inventor: KRUSE CORNELIS G , HES ROELOF VAN , SMID PIETER , TULP MARTINUS TH M
IPC: C07D401/14 , A61K31/505 , A61P25/00 , C07D471/04 , C07D487/04 , C07D513/04
CPC classification number: C07D401/14 , C07D471/04 , C07D487/04 , C07D513/04
-
15.
公开(公告)号:AR052872A1
公开(公告)日:2007-04-11
申请号:ARP060100144
申请日:2006-01-13
Applicant: SOLVAY PHARM BV
Inventor: TURSKI LECHOSLAW , VAN VLIET BERNARD J , REMIE RENE , VAN DER HEIJDEN , TULP MARTINUS TH M
IPC: A61K31/551 , A61P27/16 , A61P43/00
Abstract: Uso de 8,9-dimetil-5-fenil-11H-1,3-dioxolo [4,5-h] imidazo [1,2-c] [2,3]benzo-diazepina: formula 1, los tautomeros y N-oxidos de la misma, como así también de las sales, hidratos y solvatos farmacologicamente aceptables de este compuesto y sus tautomeros y N- oxidos, para la preparacion de una composicion farmacéutica para el tratamiento, mejora o prevencion de mareo, incluyendo vértigo y trastorno de meniére.
-
公开(公告)号:AR050443A1
公开(公告)日:2006-10-25
申请号:ARP050103195
申请日:2005-08-01
Applicant: SOLVAY PHARM BV
Inventor: FUCHS EBERHARD , CZEH BOLDIZSAR , HESSELINK MAYKE B , THOLE HUBERT , TULP MARTINUS TH M
IPC: A61K31/4995 , A61K31/404 , A61K31/495 , A61K31/551 , A61K31/5513 , A61P5/26 , A61P15/02
Abstract: Se refiere al uso de antagonistas del receptor de neuroquinina-1 como terapia de reemplazo de testosterona. En un aspecto adicional, la invencion se refiere al uso de antagonistas del receptor de neuroquinina-1 para la preparacion de medicamentos para tratar estados o condiciones asociados con bajos niveles de testosterona, en pacientes que tienen niveles deficientes de testosterona. En otro aspecto la invencion se refiere al uso de antagonistas del receptor de neuroquinina-1 para la preparacion de medicamentos para tratar hipogonadismo en hombres. Reivindicacion 6: Uso de acuerdo con lo reivindicado en caulquiera de las reivindicaciones 1-5, caracterizado porque dicho antagonista de neuroquinina-1 es un compuesto con la formula general 1 en donde -R1 representa fenilo, 2-indolilo, 3-indolilo, 3-indazolilo o benzo [b]tiofen-3-ilo, opcionalmente sustituido con halogeno o alquilo (C1-3), -R2 y R3 independientemente representan halogeno, H, OCH3, CH3 y CF3, -R4, R5 y R6 independientemente representan H, OH, O alquilo ( C1-4), CH2OH, NH2, dialquil(C1-3)N, pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo o morfolin-4-ilo, sustituido con uno o dos grupos metilo o metoximetilo, morfolin-4-ilamino, morfolin-4- ilmetilo, imidazol-1-ilo, tiomorfolin-4-ilo, 1,1-dioxo-tiomorfolin-4-ilo o 3-oxa-8-azabiciclo[3.2.1]oct-8-ilo; R4 y R5 juntos pueden representar un grupo ceto, un grupo 1,3-dioxan-2-ilo, X representa O o S, n tiene el valor 1, 2 o 3, a es el átomo de carbono asimétrico 8a, 9a o 10a cuando n es igual a 1, 2 o 3 respectivamente.
-
公开(公告)号:AU2005313387A1
公开(公告)日:2006-06-15
申请号:AU2005313387
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: KRUSE CORNELIS G , HES ROELOF VAN , TULP MARTINUS TH M , SMID PIETER
IPC: C07D401/14 , A61K31/519 , A61P25/00 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The present invention relates to a group of novel tetrahydropyridin-4-yl indoles with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D 2 receptors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said tetrahydropyridin-4-yl indoles. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The invention relates to novel tetrahydropyridin -4-yl indoles of the formula (I) and tautomers, stereoisomers, prodrugs, N -oxides, pharmacologically acceptable salts, hydrates and solvates thereof , wherein: - R 1 is hydrogen, halogen, alkyl (C 1-3 ) or alkoxy(C 1-3 ), CN or CF 3 , - R 2 is hydrogen or alkyl (C 1-3 ), R 3 is hydrogen or alkyl (C 1-3 ), - Z is hydrogen or alkyl (C 1-3 ), alkoxy(C 1-3 ) or alkylthio(C 1-3 ), - A is hydrogen or alkyl (C 1-3 ), or - A and Z together form a saturated or (partly) unsaturated 5 - or 6- membered ring which may be substituted with halogen, alkyl (C 1-3 ) or phenyl, in which ring Z represents carbon, sulfur of nitrogen .
-
18.
公开(公告)号:AU2005313386A1
公开(公告)日:2006-06-15
申请号:AU2005313386
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: SMID PIETER , HES ROELOF VAN , KRUSE CORNELIS G , TULP MARTINUS TH M
IPC: C07D319/18 , A61K31/496 , A61P25/28 , C07D215/38 , C07D265/36 , C07D295/12 , C07D307/82 , C07D311/18 , C07D321/10
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine -D2 receptors and to methods for the preparation of these compounds. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula ( 1 ) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:AT285407T
公开(公告)日:2005-01-15
申请号:AT02784838
申请日:2002-07-03
Applicant: SOLVAY PHARM BV
Inventor: VAN MAARSEVEEN JAN H , VAN SCHARRENBURG GUSTAAF J M , TULP MARTINUS TH M , MCCREARY ANDREW C , IWEMA BAKKER WOUTER I , COOLEN HEIN K A C , HERREMANS ARNOLDUS H J , VAN DEN HOOGENBAND ADRIANUS
IPC: A61K31/495 , A61K31/496 , A61K31/5377 , A61K31/541 , A61P1/00 , A61P1/04 , A61P1/08 , A61P3/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P13/02 , A61P13/10 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D241/04 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/14 , C07D471/04 , C07D265/00 , C07D241/00 , C07D207/00
Abstract: The present invention relates to a group of novel piperazine oxime derivatives having interesting NK-1 antagonistic activity. The invention relates to compounds of the general formula (1) wherein: X represents phenyl or pyridyl substituted with 1 or 2 substituents from the group CH 3 , CF 3 , OCH 3 , halogen, cyano and 5-CF 3 -tetrazol-1-yl; Y represents 2- or 3-indolyl, phenyl, 7-aza-indol-3-yl or 3-indazolyl, 2-naphthyl, 3-benzo[b]thiophenyl, 2-benzofuranyl, which groups may be substituted with one or more halogen or alkyl (1-3C); n has the value 0-3; m has the value 0-2; R 1 represents NH 2 , NH-alkyl (1-3C), dialkyl (1-3C)N, morpholino or morpholino substituted with one or two methyl and/or methoxymethyl groups, thiomorpholino, 1,1-dioxothiomorpholino, 2-, 3- or 4-pyridyl or 4-CH 3 -piperazinyl; R 2 is hydrogen, alkyl (1-4C) or phenyl, or R 2 together with (CH 2 ) m wherein m is 1, and the intermediate carbon, nitrogen and oxygen atoms forms an isoxazolyl or a 4,5-dihydroisoxazolyl group; R 3 and R 4 independently represent hydrogen or methyl, or R 3 and R 4 together are oxygen. The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions comprising compounds with formula (1) as an active ingredient and the use of these compounds for the treatment of disorders in which neurokinin-1 receptors are involved
-
公开(公告)号:CA2446726A1
公开(公告)日:2003-01-23
申请号:CA2446726
申请日:2002-07-03
Applicant: SOLVAY PHARM BV
Inventor: MCCREARY ANDREW C , IWEMA BAKKER WOUTER I , HERREMANS ARNOLDUS H J , COOLEN HEIN K A C , VAN MAARSEVEEN JAN H , VAN DEN HOOGENBAND ADRIANUS , TULP MARTINUS TH M , VAN SCHARRENBURG GUSTAAF J M
IPC: A61K31/495 , A61K31/496 , A61K31/5377 , A61K31/541 , A61P1/00 , A61P1/04 , A61P1/08 , A61P3/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P13/02 , A61P13/10 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D241/04 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/14 , C07D471/04 , C07D207/00 , C07D241/00 , C07D265/00
Abstract: The present invention relates to a group of novel piperazine oxime derivativ es having interesting NK-1 antagonistic activity. The invention relates to compounds of the general formula (1) wherein:X represents phenyl or pyridyl substituted with 1 or 2 substituents from the group CH3, CF3, OCH3, halogen, cyano and 5-CF3-tetrazol-1-yl; Y represents 2- or 3-indolyl, phenyl, 7-aza- indol-3-yl or 3-indazolyl, 2-naphthyl, 3-benzo[b]thiophenyl, 2-benzofuranyl, which groups may be substituted with one or more halogen or alkyl (1-3C); n has the value 0-3; m has the value 0-2; R1 represents NH2, NH-alkyl (1-3C), dialkyl (1-3C)N, morpholino or morpholino substituted with one or two methyl and/or methoxymethyl groups, thiomorpholino, 1,1-dioxothiomorpholino, 2-, 3- or 4-pyridyl or 4-CH3-piperazinyl; R2 is hydrogen, alkyl (1-4C) or phenyl, o r R2 together with (CH2)m wherein m is 1, and the intermediate carbon, nitroge n and oxygen atoms forms an isoxazolyl or a 4,5-dihydroisoxazolyl group; R3 an d R4 independently represent hydrogen or methyl, or R3 and R4 together are oxygen. The invention also relates to a method for the preparation of the novel compounds, and to pharmaceutical compositions comprising compounds wit h formula (1) as an active ingredient and the use of these compounds for the treatment of disorders in which neurokinin-1 receptors are involved.
-
-
-
-
-
-
-
-
-